News Release Details
Phio Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders
The Company advises shareholders that the proxy statement dated
The Company encourages any stockholders that have not received communications from their brokers or banks or are uncertain if their shares have been voted to contact the Company's proxy specialists at the number listed below in order to help facilitate the voting of shares.
The record date for the Special Meeting remains
For questions relating to the voting of shares or to request additional or misplaced proxy voting materials, the Company's proxy solicitor, Georgeson, may be reached at 1-866-695-6078
Stockholders who hold their shares through a bank or broker can vote through Broadridge using one of the methods below:
- Go to www.proxyvote.com.
- Have your voting instruction form in hand when you access the website.
- To cast your vote, enter the information that is printed in the box marked by the arrow on the voting instruction form and follow the directions given.
Vote by Telephone:
- Call the toll-free number found on the enclosed voting instruction form to transmit your voting instructions.
- Have your voting instruction form in hand when you call.
- To cast your vote, you will need the information that is printed in the box marked by the arrow on the voting instruction form and follow the directions given.
Vote by Mail:
- You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.
- Mark, sign and date your voting instruction form and return in the enclosed postage-paid envelope provided.
Registered stockholders (stockholders who do not hold their shares through a bank or broker) are urged to complete, sign, date and mail their proxy card at their earliest convenience. Any registered stockholder who would like to vote by telephone may call 1-800-652-8683. Registered stockholders may also vote online at www.investorvote.com/PHIO.
A copy of the Company's proxy statement as previously filed with the
YOUR PARTICIPATION IS IMPORTANT – PLEASE VOTE TODAY!
About Phio Pharmaceuticals Corp.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, expected duration of available cash runway, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.